HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Hillhouse Capital Related

463.703

+4.3720.95%

Number of Gainers:35

Number of Losers:16

Number of Flat:4

PE:- -

High:463.801

Open:459.330

Low:450.664

Close:459.330

Loading ...

Xtep International's Core Brand Logs Mid-Single-Digit Retail Sell-Through Growth in Q1

MT Newswires Live

Zhaoke Ophthalmology Enrols First Patient in Dry Eye Disease Drug Trial

MT Newswires Live

China Tower Logs 8.6% Jump in Q1 Profit

MT Newswires Live

Hansoh Pharma's HS-20093 Drug Gets Another Breakthrough Therapy Designation in China

MT Newswires Live

3SBio's Lung Cancer Drug Gets Breakthrough Therapy Designation in China

MT Newswires Live

BRIEF-Xiabuxiabu Catering Management (China) To Acquire 40% Stake In Xiabuxiabu (China) Food

BRIEF-Hansoh Pharmaceutical's Targeted Antibody Drug Conjugate Gets NMPA Breakthrough-Therapy-Designated-Drug

Xiabuxiabu Catering Management (China) - to Acquire 40% Stake in Xiabuxiabu (China) Food for RMB89 Mln

THOMSON REUTERS

Hansoh Pharmaceutical - Nmpa Granted Breakthrough-Therapy-Designated-Drug for B7-H3-Targeted Antibody-Drug Conjugate Hs-20093

THOMSON REUTERS

BRIEF-3Sbio Says 707 Injection (Anti-Vegf/Pd-1 Bispecific Antibody) Granted Breakthrough Therapy Designation By NMPA

BRIEF-China Tower Q1 EBITDA Margin 69.8%

BRIEF-UBS Group's Long Position In H-Shares Of Wuxi Apptec Decreased - HKEX

3SBio - 707 Injection (Anti-Vegf/Pd-1 Bispecific Antibody) Granted Breakthrough Therapy Designation by Nmpa

THOMSON REUTERS

Greater China Stocks Close Mixed; Hong Kong Leads Gainers

China Tower - Qtrly Profit Attributable to Owners of Company Was RMB3,024 Mln

THOMSON REUTERS

Zhaoke Ophthalmology, Interpharma Strike Thailand Drug Distribution Deal

MT Newswires Live

BRIEF-Zhaoke Ophthalmology Enters 3 Distribution Agreements With Interpharma

Morgan Stanley's Short Position in H Shares of WuXi AppTec Reduces to 4.03% From 5.09% on April 10 - HKEX

THOMSON REUTERS

Zhaoke Ophthalmology - Enters 3 Distribution Agreements With Interpharma to Commercialize Nvk002, Brimocho Tm Pf & 6 Glaucoma Drugs in Thailand

THOMSON REUTERS

Hansoh Pharma Gets Clinical Trial Nod in China for Cancer Drug

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK1583/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1583","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","market":"HK","secType":"PLATE","nameCN":"Hillhouse Capital Related","latestPrice":463.70267,"timestamp":1744877287948,"preClose":459.33044,"halted":0,"volume":609142339,"delay":0,"changeRate":0.009519,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":4.372223,"latestTime":"04-17 16:00:00","open":459.33044,"high":463.80103,"low":450.66434,"amount":13248155396,"amplitude":0.0286,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745285400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1744853400000,1744862400000],[1744866000000,1744876800000]],"pbRate":2.20563,"peRate":21.792246,"turnoverRate":0.004229,"increases":34,"decrements":17,"flats":3,"marketCap":2588166171648,"floatMarketCap":2054256131328},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","high":463.80103,"amplitude":0.0286,"preClose":459.33044,"low":450.66434,"pbRate":"2.20563","latestPrice":463.70267,"volume":609142339,"delay":0,"open":459.33044,"prevYearClose":446.93042,"prevWeekClose":463.703,"prevMonthClose":505.776,"prevQuarterClose":505.776,"fiveDayClose":468.236,"twentyDayClose":532.354,"sixtyDayClose":436.667,"secType":"PLATE","market":"HK","turnoverRate":0.004229,"peRate":21.792246,"marketCap":2588166171648,"floatMarketCap":2054256131328,"timestamp":1744877287948,"nameCN":"Hillhouse Capital Related"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1583\",,,,undefined,":{"bkCode":"BK1583","up":35,"down":16,"flat":4},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1583\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529880971","title":"Xtep International's Core Brand Logs Mid-Single-Digit Retail Sell-Through Growth in Q1","url":"https://stock-news.laohu8.com/highlight/detail?id=2529880971","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529880971?lang=en_us&edition=fundamental","pubTime":"2025-04-21 21:03","pubTimestamp":1745240627,"startTime":"0","endTime":"0","summary":"Xtep International  saw mid-single-digit year-on-year retail sell-through growth for its Core Xtep brand in the first quarter of 2025, an April 17 Hong Kong bourse filing said.Retail discount level for the quarter was between 25% and 30%, while channel inventory turnover stood at around four months.For its Saucony portfolio, retail sell-through growth stood at more than 40% from the year-ago period.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1168","BK1512","BK1583","01368","BK1502"],"gpt_icon":0},{"id":"2529874657","title":"Zhaoke Ophthalmology Enrols First Patient in Dry Eye Disease Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2529874657","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529874657?lang=en_us&edition=fundamental","pubTime":"2025-04-21 18:58","pubTimestamp":1745233118,"startTime":"0","endTime":"0","summary":"Zhaoke Ophthalmology  has enrolled the first patient in the phase III clinical trial of Cyclosporine  Ophthalmic Gel, an April 17 Hong Kong bourse filing said.The ophthalmic pharmaceutical company is testing the drug for the treatment of moderate to severe dry eye disease.The trial will involve 25 centers and enroll a total of 360 patients.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1574","06622","BK1583","BK1587","BK1191"],"gpt_icon":0},{"id":"2529847373","title":"China Tower Logs 8.6% Jump in Q1 Profit","url":"https://stock-news.laohu8.com/highlight/detail?id=2529847373","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529847373?lang=en_us&edition=fundamental","pubTime":"2025-04-21 15:17","pubTimestamp":1745219874,"startTime":"0","endTime":"0","summary":"China Tower  recorded an attributable profit of 3.02 billion yuan in the first quarter of 2025, up 8.6% from 2.78 billion yuan a year prior, an April 17 Hong Kong bourse filing said.Operating revenue for the tower infrastructure service provider for the three months rose by 3.3% to 24.8 billion yuan from 24 billion yuan in the year-ago period.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["00788","IE00BG0RBZ43.SGD","IE00BHRH8D16.HKD","BK1133","BK1583","BK1589","BK1529","BK1506","IE00BHRH8C09.USD","LU0823413660.USD","LU0823413587.USD","BK1521"],"gpt_icon":0},{"id":"2528320460","title":"Hansoh Pharma's HS-20093 Drug Gets Another Breakthrough Therapy Designation in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2528320460","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528320460?lang=en_us&edition=fundamental","pubTime":"2025-04-18 16:26","pubTimestamp":1744964786,"startTime":"0","endTime":"0","summary":"Hansoh Pharmaceutical Group's (HKG:3692) antibody-drug conjugate HS-20093 received another breakthrough therapy designation (BTD) from China's National Medical Products Administration.This new designa","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1589","BK1191","BK1583","03692"],"gpt_icon":0},{"id":"2528508155","title":"3SBio's Lung Cancer Drug Gets Breakthrough Therapy Designation in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2528508155","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528508155?lang=en_us&edition=fundamental","pubTime":"2025-04-18 12:19","pubTimestamp":1744949994,"startTime":"0","endTime":"0","summary":"3SBio  said its 707 injection was granted a breakthrough therapy designation by China's National Medical Products Administration, according to a late Thursday bourse filing.This designation provides benefits for 707's development as a first-line treatment for PD-L1-positive locally advanced or metastatic non-small cell lung cancer, the filing stated.Drugs with that designation are entitled to policy support, prioritized communication resources, enhanced guidance, and accelerated development.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","01530","BK1593","BK1583"],"gpt_icon":0},{"id":"2528747557","title":"BRIEF-Xiabuxiabu Catering Management (China) To Acquire 40% Stake In Xiabuxiabu (China) Food","url":"https://stock-news.laohu8.com/highlight/detail?id=2528747557","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528747557?lang=en_us&edition=fundamental","pubTime":"2025-04-17 23:25","pubTimestamp":1744903530,"startTime":"0","endTime":"0","summary":"BRIEF-Xiabuxiabu Catering Management  To Acquire 40% Stake In Xiabuxiabu  Food April 17  - Xiabuxiabu Catering Management  Holdings Co Ltd 0520.HK:TO ACQUIRE 40% STAKE IN XIABUXIABU  FOOD FOR RMB89 MILLIONFurther company coverage: 0520.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QV1AR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1233","BK1583","BK1604","00520"],"gpt_icon":0},{"id":"2528744308","title":"BRIEF-Hansoh Pharmaceutical's Targeted Antibody Drug Conjugate Gets NMPA Breakthrough-Therapy-Designated-Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2528744308","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528744308?lang=en_us&edition=fundamental","pubTime":"2025-04-17 22:57","pubTimestamp":1744901865,"startTime":"0","endTime":"0","summary":"BRIEF-Hansoh Pharmaceutical's Targeted Antibody Drug Conjugate Gets NMPA Breakthrough-Therapy-Designated-DrugApril 17  - Hansoh Pharmaceutical Group Company Ltd 3692.HK:NMPA GRANTED BREAKTHROUGH-THERAPY-DESIGNATED-DRUG FOR B7-H3-TARGETED ANTIBODY-DRUG CONJUGATE HS-20093Further company coverage: 3692.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QV2XM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","BK1191","BK1583","03692"],"gpt_icon":0},{"id":"2528741975","title":"Xiabuxiabu Catering Management (China) - to Acquire 40% Stake in Xiabuxiabu (China) Food for RMB89 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2528741975","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528741975?lang=en_us&edition=fundamental","pubTime":"2025-04-17 22:45","pubTimestamp":1744901156,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QV1AR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","BK1233","BK1604","00520"],"gpt_icon":0},{"id":"2528271958","title":"Hansoh Pharmaceutical - Nmpa Granted Breakthrough-Therapy-Designated-Drug for B7-H3-Targeted Antibody-Drug Conjugate Hs-20093","url":"https://stock-news.laohu8.com/highlight/detail?id=2528271958","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528271958?lang=en_us&edition=fundamental","pubTime":"2025-04-17 20:13","pubTimestamp":1744892005,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QV2XM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["03692","BK1583","BK1589","BK1191"],"gpt_icon":0},{"id":"2528919794","title":"BRIEF-3Sbio Says 707 Injection (Anti-Vegf/Pd-1 Bispecific Antibody) Granted Breakthrough Therapy Designation By NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2528919794","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528919794?lang=en_us&edition=fundamental","pubTime":"2025-04-17 18:29","pubTimestamp":1744885740,"startTime":"0","endTime":"0","summary":"BRIEF-3Sbio Says 707 Injection  Granted Breakthrough Therapy Designation By NMPAApril 17  - 3SBio Inc 1530.HK:707 INJECTION  GRANTED BREAKTHROUGH THERAPY DESIGNATION BY NMPAFurther company coverage: 1530.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QU2L4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","01530","BK1593","BK1161"],"gpt_icon":0},{"id":"2528791096","title":"BRIEF-China Tower Q1 EBITDA Margin 69.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2528791096","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528791096?lang=en_us&edition=fundamental","pubTime":"2025-04-17 18:22","pubTimestamp":1744885374,"startTime":"0","endTime":"0","summary":"BRIEF-China Tower Q1 EBITDA Margin 69.8%April 17 (Reuters) - China Tower 0788.HK:Q1 EBITDA MARGIN 69.8%Q1 EBITDA RMB 17,295 MILLIONQ1 REVENUE RMB 24,771 MILLIONQTRLY PROFIT ATTRIBUTABLE TO OWNERS OF COMPANY WAS RMB3,024 MILLIONFurther company coverage: 0788.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nPLXBB1569:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1506","BK1583","IE00BHRH8C09.USD","IE00BG0RBZ43.SGD","BK1529","IE00BHRH8D16.HKD","BK1133","LU0823413587.USD","BK1521","00788","LU0823413660.USD","BK1589"],"gpt_icon":0},{"id":"2528991167","title":"BRIEF-UBS Group's Long Position In H-Shares Of Wuxi Apptec Decreased - HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2528991167","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528991167?lang=en_us&edition=fundamental","pubTime":"2025-04-17 18:04","pubTimestamp":1744884286,"startTime":"0","endTime":"0","summary":"BRIEF-UBS Group's Long Position In H-Shares Of Wuxi Apptec Decreased - HKEXApril 17 (Reuters) - UBS GROUP'S LONG POSITION IN H-SHARES OF WUXI APPTEC DECREASES TO 6.72% ON APRIL 11 FROM 7.39% - HKEXFurther company coverage: 2359.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QV1EE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1997244956.HKD","02359","LU2045819591.USD","BK1576","LU1997245177.USD","LU0708995583.HKD","LU0052750758.USD","LU0320764599.SGD","603259","BK0216","LU1046422090.SGD","LU2125910500.SGD","LU2495084118.USD","LU0456842615.SGD","LU2242644610.SGD","BK1583","LU1997245094.SGD","LU2488822045.USD","BK1141"],"gpt_icon":0},{"id":"2528769933","title":"3SBio -  707 Injection (Anti-Vegf/Pd-1 Bispecific Antibody) Granted Breakthrough Therapy Designation by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2528769933","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528769933?lang=en_us&edition=fundamental","pubTime":"2025-04-17 16:32","pubTimestamp":1744878747,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QU2L4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1593","01530","BK1161","BK1583"],"gpt_icon":0},{"id":"2528276998","title":"Greater China Stocks Close Mixed; Hong Kong Leads Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2528276998","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528276998?lang=en_us&edition=fundamental","pubTime":"2025-04-17 16:31","pubTimestamp":1744878660,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Stocks in Greater China were mixed on Thursday.Hong Kong's Hang Seng Index gained 1.6% to 21395.14, and China's Shanghai Composite Index rose 0.1% to 3280.34. The Taiwan Taiex index slipped 0.7% to 19338.73.China Resources Mixc Lifestyle Services Ltd. posted the largest decline among companies on the Hang Seng, falling 4.0%, followed by shares of WH Group Ltd., which fell 3.0%. Shares of China Mengniu Dairy Co. Ltd. fell 1.3%.Among large mainland China stocks, Shanghai Chemspec Corp. A was the biggest gainer during the session, surging 20%, and Wuxi Chipown Micro-Electronics Ltd. A surged 13%. Jiangsu Eazytec Co. Ltd. A rounded out the top three movers on Thursday, as shares surged 12%.In Taiwan, Macnica Anstek Inc. was the biggest gainer among large companies during the session, surging 10%, and Polaris Group surged 10% Iron Force Industrial Co. Ltd. rounded out the top three movers, as shar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1023057109.AUD","LU0672654166.SGD","BK0262","01209","LU0385154629.USD","BK1237","BK1555","LU0471298777.SGD","BK0231","BK1510","LU0274383008.USD","LU0307460666.USD","688508","BK1589","LU0328353924.USD","LU0163747925.USD","SG9999002950.SGD","LU0106959298.USD","LU0541502299.USD","BK1258","SGXZ90724238.SGD","02319","LU0072462343.USD","80291","IE00B031J352.USD","LU0173614495.USD","LU0650527681.SGD","LU1051768304.USD","688258","IE00B031HY20.USD","SG9999001069.SGD","BK1583","603800","00291","BK1597","LU0251143458.SGD","LU1224709979.USD","600540","LU1102505929.USD","BK0176","LU1515016050.SGD","IE00B97KM107.HKD","CRHKY","LU1769817096.USD","BK1543","600735","LU0211977185.USD","00288","BK0028","00960"],"gpt_icon":0},{"id":"2528769608","title":"China Tower - Qtrly Profit Attributable to Owners of Company Was RMB3,024 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2528769608","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528769608?lang=en_us&edition=fundamental","pubTime":"2025-04-17 16:30","pubTimestamp":1744878627,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nPLXBB1569:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0823413660.USD","BK1583","00788","LU0823413587.USD","BK1529","BK1133","BK1589","BK1521","BK1506","IE00BHRH8C09.USD","IE00BG0RBZ43.SGD","IE00BHRH8D16.HKD"],"gpt_icon":0},{"id":"2527292479","title":"Zhaoke Ophthalmology, Interpharma Strike Thailand Drug Distribution Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2527292479","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527292479?lang=en_us&edition=fundamental","pubTime":"2025-04-16 19:16","pubTimestamp":1744802199,"startTime":"0","endTime":"0","summary":"Zhaoke Ophthalmology  entered into three distribution and supply agreements with Interpharma PCL  to commercialize several ophthalmic drugs in Thailand, according to a Wednesday filing with the Hong Kong Exchange.The deals cover NVK002 for myopia progression control, BRIMOCHOL PF for presbyopia, and six generic glaucoma drugs: Bimatoprost, Bimatoprost Timolol, Latanoprost, Latanoprost Timolol, Travoprost, and Travoprost Timolol.Under the agreements, Interpharma gains exclusive rights to import, distribute, market, and sell Zhaoke's products in Thailand and will manage local drug registrations. Zhaoke will then receive non-refundable upfront payments and milestone-based payments.Shares of Interpharma closed nearly 5% higher on Wednesday, while those of Zhaoke slipped 3%.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1583","BK1587","BK1191","BK1574","06622"],"gpt_icon":0},{"id":"2527635295","title":"BRIEF-Zhaoke Ophthalmology Enters 3 Distribution Agreements With Interpharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2527635295","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527635295?lang=en_us&edition=fundamental","pubTime":"2025-04-16 18:29","pubTimestamp":1744799368,"startTime":"0","endTime":"0","summary":"BRIEF-Zhaoke Ophthalmology Enters 3 Distribution Agreements With InterpharmaApril 16  - Zhaoke Ophthalmology Ltd 6622.HK:ENTERS 3 DISTRIBUTION AGREEMENTS WITH INTERPHARMA TO COMMERCIALIZE NVK002, BRIMOCHO TM PF & 6 GLAUCOMA DRUGS IN THAILANDFurther company coverage: 6622.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nFWN3QT2LO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1574","06622","BK1191","BK1583"],"gpt_icon":0},{"id":"2527091266","title":"Morgan Stanley's Short Position in H Shares of WuXi AppTec  Reduces to 4.03% From 5.09% on April 10 - HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2527091266","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527091266?lang=en_us&edition=fundamental","pubTime":"2025-04-16 17:20","pubTimestamp":1744795234,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nFWN3QT2LQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","LU1997245177.USD","BK0216","BK1141","LU2125910500.SGD","LU1997244956.HKD","LU2495084118.USD","LU0052750758.USD","02359","603259","BK1576","LU1997245094.SGD","LU0456842615.SGD","LU2045819591.USD","LU0320764599.SGD","LU0708995583.HKD","LU2242644610.SGD","LU2488822045.USD","LU1046422090.SGD"],"gpt_icon":0},{"id":"2527226538","title":"Zhaoke Ophthalmology - Enters 3 Distribution Agreements With Interpharma to Commercialize Nvk002, Brimocho Tm Pf & 6 Glaucoma Drugs in Thailand","url":"https://stock-news.laohu8.com/highlight/detail?id=2527226538","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527226538?lang=en_us&edition=fundamental","pubTime":"2025-04-16 17:07","pubTimestamp":1744794421,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nFWN3QT2LO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1587","BK1583","06622","BK1191","BK1574"],"gpt_icon":0},{"id":"2527203234","title":"Hansoh Pharma Gets Clinical Trial Nod in China for Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2527203234","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527203234?lang=en_us&edition=fundamental","pubTime":"2025-04-16 14:13","pubTimestamp":1744783998,"startTime":"0","endTime":"0","summary":"Hansoh Pharmaceutical Group  obtained clinical trial approval in China for HS-10529, according to a late Tuesday disclosure with the Hong Kong Exchange.HS-10529 will be investigated as a treatment for advanced solid tumors, including pancreatic cancer, colorectal cancer, and non-small cell lung cancer with KRAS G12D mutations.The stock slipped over 2% in afternoon trade on Wednesday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","BK1589","03692","BK1583"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":69,"code":"91000000","status":"200"}]}}